Company Overview
Snapshot
Founded in July 2019 by Boaz Shenhav, Bio Refine operates with 1–10 employees. The company has raised $900,000 across two funding rounds from one investor. In October 2025, Bio Refine secured follow-on funding from Peregrine Ventures.
Business overview
Bio Refine is a Health Tech & Life Sciences company focused on developing an endovascular annuloplasty remodeling system for the repair of mitral and tricuspid heart valves. This technology offers an implantless solution designed to treat patients who are currently at high risk for open surgery. The system utilizes a standard endovascular approach, aiming for a safe, repeatable procedure that does not preclude ancillary interventions. Bio Refine operates in the Medical Devices and Medical Treatment & Therapeutics sectors, serving healthcare providers.
Log in to access full profile ›Company Intelligence Q&A
- What is Bio Refine's core technology?
- Bio Refine has developed an endovascular annuloplasty remodeling system designed for the repair of mitral and tricuspid heart valves without the need for an implant.
- Who founded Bio Refine?
- Bio Refine was co-founded by Boaz Shenhav.
- When was Bio Refine founded?
- Bio Refine was founded in July 2019.
- What is the primary benefit of Bio Refine's solution?
- The technology offers a treatment option for patients who cannot undergo traditional open surgery due to high risks, providing a safe, implant-free, and repeatable procedure that uses a standard endovascular approach.
- Which investor has participated in Bio Refine's funding rounds?
- Peregrine Ventures has participated in Bio Refine's funding rounds, including a follow-on investment in October 2025 and an initial investment in February 2023.